Key result
Whole blood mRNA profiling identifies 259 genes distinguishing post-SAH vasospasm from uncomplicated cases.
Why the study?
Few studies have examined mRNA expression in whole blood cells that might contribute to vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Does mRNA expression in whole blood differ between SAH patients with and without vasospasm?
Case-Control (n=50)
No
Does mRNA expression in whole blood differ between SAH patients with and without vasospasm?
mRNA expression profiles in whole blood can distinguish SAH patients with vasospasm from those without, implicating coagulation and immune system pathways in its pathogenesis.
Supports blood-based biomarker exploration in SAH vasospasm; hypothesis-generating and requires prospective validation before clinical use.
BACKGROUND: Though there are many biomarker studies of plasma and serum in patients with aneurysmal subarachnoid hemorrhage (SAH), few have examined blood cells that might contribute to vasospasm. In this study, we evaluated inflammatory and prothrombotic pathways by examining mRNA expression in whole blood of SAH patients with and without vasospasm. METHODS: Adult SAH patients with vasospasm (n = 29) and without vasospasm (n = 21) were matched for sex, race/ethnicity, and aneurysm treatment method. Diagnosis of vasospasm was made by angiography. mRNA expression was measured by Affymetrix Human Exon 1.0 ST Arrays. SAH patients with vasospasm were compared to those without vasospasm by ANCOVA to identify differential gene, exon, and alternatively spliced transcript expression. Analyses were adjusted for age, batch, and time of blood draw after SAH. RESULTS: At the gene level, there were 259 differentially expressed genes between SAH patients with vasospasm compared to patients without (false discovery rate < 0.05, |fold change| ≥ 1.2). At the exon level, 1210 exons representing 1093 genes were differentially regulated between the two groups (P < 0.005, ≥ 1.2 |fold change|). Principal components analysis segregated SAH patients with and without vasospasm. Signaling pathways for the 1093 vasospasm-related genes included adrenergic, P2Y, ET-1, NO, sildenafil, renin-angiotensin, thrombin, CCR3, CXCR4, MIF, fMLP, PKA, PKC, CRH, PPARα/RXRα, and calcium. Genes predicted to be alternatively spliced included IL23A, RSU1, PAQR6, and TRIP6. CONCLUSIONS: This is the first study to demonstrate that mRNA expression in whole blood distinguishes SAH patients with vasospasm from those without vasospasm and supports a role of coagulation and immune systems in vasospasm.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2019) conducted a case-control in Aneurysmal Subarachnoid Hemorrhage (SAH) (n=50). Angiographic vasospasm vs. SAH without vasospasm was evaluated on Differential mRNA expression (genes and exons) in whole blood (p=<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: